Merrimack Pharmaceuticals (MACK) Stock: Tumbles On Trial Failure
Merrimack Pharmaceuticals Inc (NASDAQ: MACK) is having an incredibly rough start to the trading session in the pre-market hours this morning, and for good reason. The company was forced to terminate a drug trial due to futility. So, it comes as no surprise that upset investors are sending the stock tumbling. Today, we’ll talk about: … Read more